Leawood, Kansas, May 14, 2026. Milestone validation paves way for FDA-cleared clinical trial targeting speech restoration in patients with ALS, stroke, and spinal cord injury.

Story Highlights

  • First-ever human implantation of the Connexus® BCI performed at the University of Michigan during a planned epilepsy resection surgery.
  • Device successfully recorded high-resolution neural signals at the individual-neuron level, confirming safety in human tissue and signal capture precision.
  • Paradromics holds an FDA Investigational Device Exemption for the Connect-One Early Feasibility Study, making it the first fully implantable BCI cleared to evaluate speech restoration.

Prevail Venture Capital today highlighted a landmark clinical milestone achieved by Paradromics, Inc., a portfolio company developing high-resolution brain-computer interface technology for individuals with severe motor impairments.

On May 14, 2026, at the University of Michigan, Paradromics completed the first-ever human implantation of its Connexus® Brain-Computer Interface. The procedure was performed during a planned epilepsy resection surgery, during which the Connexus device was temporarily implanted and removed over approximately 20 minutes. The device successfully recorded high-resolution neural signals at the level of individual neurons, confirming both safety in human tissue and the precision of its signal capture capability.

The Connexus® BCI is a fully implantable device smaller than a dime, equipped with 420 micro-needle electrodes that penetrate cortical tissue to record signals directly from individual neurons. This intracortical approach enables higher-resolution neural data than surface-mounted or intravascular alternatives, which the company believes is essential for accurate real-time decoding of intended speech.

Paradromics holds an Investigational Device Exemption from the FDA for the Connect-One Early Feasibility Study, making it the first company cleared to evaluate a fully implantable BCI for speech restoration. The clinical study will evaluate the Connexus device in patients with severe speech impairment resulting from conditions including ALS, stroke, and spinal cord injury, and the first human implant provided the safety and signal quality data required to support progression of that trial.

The company has raised $88.7 million across 13 funding rounds from 28 investors and currently employs more than 100 people.

About Paradromics

Paradromics is a neurotechnology company developing the Connexus® Brain-Computer Interface for individuals with severe motor and speech impairments. The company’s mission is to restore communication to people who have lost the ability to speak due to conditions such as ALS, stroke, and spinal cord injury. Paradromics is headquartered in Austin, Texas. For more information, visit paradromics.com.

About Prevail Venture Capital

Prevail Venture Capital is a Leawood, Kansas venture firm investing out of a $60M Fund I across MedTech & Longevity, Defense & Security Tech, Fintech, Deep Tech, AI, and Robotics. Prevail and its affiliated entities employ more than seventy people, with an experienced operating bench supporting portfolio companies across EOS, Culture Index, finance, marketing, and BD.

Media Contact: Regan Smith · Manager of Investor Relations · venture-capital@prevailiws.com · (913) 295-9500

Safe Harbor Statement: Certain statements in this press release may be forward-looking statements within the meaning of applicable securities laws. Medical device development is subject to significant regulatory, clinical, and commercial risks and uncertainties. Regulatory approvals, clinical trial outcomes, and commercialization timelines cannot be assured. These statements involve known and unknown risks and other factors that may cause actual results to differ materially from those expressed or implied. Neither Prevail Venture Capital nor Paradromics undertakes any obligation to publicly update or revise any forward-looking statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.